Impact of Hormone Receptor Status on the Behaviour of HER2 Breast Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602726" target="_blank" >RIV/61989592:15110/20:73602726 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/20:00117213 RIV/00216208:11110/20:10417331 RIV/00216208:11120/20:43920757 RIV/00216208:11150/20:10417331 a 4 dalších

Výsledek na webu

<a href="http://iv.iiarjournals.org/content/34/6/3441.full.pdf" target="_blank" >http://iv.iiarjournals.org/content/34/6/3441.full.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/invivo.12183" target="_blank" >10.21873/invivo.12183</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of Hormone Receptor Status on the Behaviour of HER2 Breast Cancer

Popis výsledku v původním jazyce

Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.

Název v anglickém jazyce

Impact of Hormone Receptor Status on the Behaviour of HER2 Breast Cancer

Popis výsledku anglicky

Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

IN VIVO

ISSN

0258-851X

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

9

Strana od-do

3441-3449

Kód UT WoS článku

000587929100043

EID výsledku v databázi Scopus

2-s2.0-85095589011